Welcome to our dedicated page for Haemonetics news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics stock.
Haemonetics Corporation reports recurring developments across its global medical technology business, including financial results, investor conference participation, product studies and U.S. regulatory actions. The company’s solutions include hospital technologies, end-to-end plasma collection technologies for plasma centers and products used by blood centers to collect blood components.
Company news frequently centers on the VASCADE MVP and VASCADE MVP XL venous vascular closure systems, the NexSys PCS Plasma Collection System and Persona technology. Updates also cover FDA approvals or 510(k) clearances, clinical evidence supporting device use, earnings releases and presentations, and communications tied to the company’s plasma, blood center and hospital markets.
Haemonetics (NYSE: HAE) will publish Q2 fiscal 2026 results at 6:00 AM ET on Thursday, November 6, 2025. The company will host a conference call with investors and analysts at 8:00 AM ET on November 6, 2025 to discuss results and answer questions.
Participants must register for teleconference access and will receive a dial-in number and personalized PIN; joining 10 minutes early is recommended. A live webcast will be available on Haemonetics' investor relations website at the provided webcast link. A replay of the call and webcast will be available for one year beginning November 6, 2025 at 11:00 AM ET.
Haemonetics Corporation (NYSE: HAE) has announced the availability of its first quarter fiscal year 2026 financial results on its Investor Relations website. The company will host a conference call and webcast with investors and analysts on August 7, 2025, at 8:00 a.m. ET to discuss the results.
The conference call requires pre-registration, and participants are recommended to join 10 minutes before the event. A replay of the conference call and webcast will be accessible for one year starting from August 7, 2025, at 11:00 a.m. ET.
Haemonetics (NYSE: HAE) has scheduled the release of its first quarter fiscal year 2026 financial results for August 7, 2025 at 6:00 am ET. The company will host a conference call with investors and analysts at 8:00 am ET on the same day to discuss the results and take questions.
Participants can access the call via teleconference after completing registration, and are encouraged to join 10 minutes before the start. A live webcast will be available on Haemonetics' investor relations website, with a replay accessible for one year starting August 7, 2025, at 11:00 am ET.
Vivasure Medical has announced two significant regulatory milestones for its PerQseal® Elite vascular closure system. The company has submitted a Premarket Approval (PMA) application to the FDA for arterial procedures and received European CE mark approval for expanded indication covering large-bore venous closure.
PerQseal Elite is positioned as the first fully bioresorbable, sutureless solution in Europe for both arterial and venous access closure. The system features a unique inside-vessel deployment mechanism and requires no pre-procedure steps, offering advantages over conventional closure techniques that leave behind materials like collagen, metal implants, or sutures.
Haemonetics Corporation (NYSE: HAE) has announced the availability of its fourth quarter and fiscal year 2025 financial results, which ended March 29, 2025, on its Investor Relations website. The company will host a conference call and webcast with investors and analysts on May 8, 2025, at 8:00 a.m. ET to discuss the results.
The company has provided access to supplemental materials including the earnings release and tables supporting fiscal 2026 total Company and Hospital reported and organic revenue growth guidance. A replay of the conference call will be available for one year starting May 8, 2025, at 11:00 a.m. ET.
Vivasure Medical has received CE Mark approval for its PerQseal Elite vascular closure system, a pioneering fully absorbable and sutureless large-bore vessel closure device. The product will be launched in select European markets this summer.
The PerQseal Elite system is specifically designed for closure following large-bore percutaneous cardiovascular procedures like TAVR and EVAR. It stands out as the first fully bioresorbable device in this category and requires no pre-procedure steps, offering improved procedural efficiency.
The device is placed from inside the vessel, providing simpler and more controlled deployment compared to conventional techniques. It restores the vessel to its natural state without leaving behind materials such as collagen, metal implants, or sutures.
Haemonetics (NYSE: HAE) has scheduled the release of its fourth quarter and fiscal year 2025 financial results for May 8, 2025 at 6:00 am ET. The company will host a conference call with investors and analysts at 8:00 am ET on the same day to discuss the results and address questions.
Participants can access the call via teleconference after completing registration, and are encouraged to join 10 minutes before the start time. A live webcast will be available on Haemonetics' investor relations website, with a replay accessible for one year starting May 8, 2025, at 11:00 am ET.
Haemonetics (NYSE: HAE) announced key executive leadership updates. Frank Chan, Ph.D. will join as Executive Vice President, Chief Operating Officer on April 7, 2025, while Roy Galvin has been appointed Executive Vice President, Chief Commercial Officer with immediate effect.
Chan, bringing over 25 years of medical device and healthcare technology leadership experience, will oversee research and development, regulatory affairs, global manufacturing, and supply chain operations. He joins from Medtronic plc, where he served as President of Acute Care & Monitoring.
Galvin, who joined Haemonetics in 2022 as President, Global Plasma and Blood Center, will now expand his responsibilities to include the Global Hospital business, directing all commercialization initiatives across the company's full product portfolio. He brings over 25 years of experience from Medtronic plc in the Neuroscience and Orthopedic markets.
Haemonetics (NYSE: HAE) has announced its participation in the upcoming Raymond James 46th Annual Institutional Investors Conference. Chris Simon, President and CEO, will engage in a fireside chat with investors on Tuesday, March 4, 2025, at 2:50 p.m. ET.
The event will be accessible to the public through a live webcast on Haemonetics' Investor Relations website and via a dedicated link. Following the presentation, a replay will be made available approximately 12 hours after the event and will remain accessible for 90 days through the company's Investor Relations website.